Summit Therapeutics Inc. SMMT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.89% | -82.59% | 301.60% | 445.48% | 399.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.37% | -61.21% | 192.01% | 242.80% | 301.20% |
| Operating Income | 8.37% | 61.21% | -192.01% | -242.80% | -301.20% |
| Income Before Tax | 10.10% | 61.87% | -201.09% | -258.11% | -312.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.10% | 61.87% | -201.09% | -258.11% | -312.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.10% | 61.87% | -201.09% | -258.11% | -312.05% |
| EBIT | 8.37% | 61.21% | -192.01% | -242.80% | -301.20% |
| EBITDA | 8.39% | 61.22% | -192.05% | -242.85% | -301.26% |
| EPS Basic | 16.26% | 63.61% | -186.74% | -244.58% | -302.84% |
| Normalized Basic EPS | 16.26% | 63.62% | -186.49% | -244.32% | -302.69% |
| EPS Diluted | 16.26% | 63.24% | -171.44% | -219.20% | -289.75% |
| Normalized Diluted EPS | 16.26% | 63.62% | -186.49% | -244.32% | -302.69% |
| Average Basic Shares Outstanding | 7.37% | 4.79% | 5.06% | 3.92% | 2.31% |
| Average Diluted Shares Outstanding | 7.37% | 4.79% | 5.06% | 3.92% | 2.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |